The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Provided herein are compositions, systems, kits, and methods for treating nervous system injuries caused by trauma or neurodegeneration or aging in a subject by administering a CSPG or SOCS3 reduction peptide (CRP and SRP respectively), or a nucleic acid sequence encoding the CRP or SRP, wherein both the CRP and SRP comprise a cell membrane penetrating domain, and a lysosome targeting domain, and the CRP further comprises a chondroitin sulfate proteoglycan (CSPG) binding domain, and the SRP further comprises a suppressor of cytokine signaling-3 (SOCS3) binding domain.

An agent for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion, and/or for treating cancer in a subject includes a targeting peptide and at least one of a detectable moiety, therapeutic agent, or a theranostic agent that is directly or indirectly linked to the targeting peptide. The targeting peptide specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment.

An agent for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion, and/or for treating cancer in a subject includes a targeting peptide and at least one of a detectable moiety, therapeutic agent, or a theranostic agent that is directly or indirectly linked to the targeting peptide. The targeting peptide specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment.

The present invention relates to a method of necrosing, causing membranolysis, or causing poration of selective cancer cells. In some aspects, the method includes administering a peptide including PPLSQETFSDLWKLL-KKWKMRRN QFW VKV QRG or ETFSDLWKLL-KKWKMRRNQFWVKVQRG to a selective cancer cell to cause necrosis, membranolysis, or poration of said selective cancer cell.

The present invention relates to a method of necrosing, causing membranolysis, or causing poration of selective cancer cells. In some aspects, the method includes administering a peptide including PPLSQETFSDLWKLL-KKWKMRRN QFW VKV QRG or ETFSDLWKLL-KKWKMRRNQFWVKVQRG to a selective cancer cell to cause necrosis, membranolysis, or poration of said selective cancer cell.

A method of treating cancer is disclosed. The method involves applying one or more direct current electric fields (DC-EFs) to a subject and administering to the subject an additional treatment selected from the group consisting of radiation, an effective amount of one or more chemotherapy agents, SapC-DOPS, anti-phosphatidylserine targeted drugs, and combinations thereof

A method of treating cancer is disclosed. The method involves applying one or more direct current electric fields (DC-EFs) to a subject and administering to the subject an additional treatment selected from the group consisting of radiation, an effective amount of one or more chemotherapy agents, SapC-DOPS, anti-phosphatidylserine targeted drugs, and combinations thereof

Methods for treating a central nervous system (CNS) tumor in a subject, comprising administering to the subject MD-NA55 in combination with a vascular endothelial growth factor A (VEGF-A) inhibitor administered at a subtherapeutic level.